Clinical Epidemiology & Public Health
Epidemiology and public health
  1. You are here:
  2. Home
  3. Journals
  4. Health
REVIEWS   (Open Access)
Contents Vol 1 (1)

Microbial Therapeutics in Cancer Treatment - Challenges and Opportunities in Breast Cancer Management

Tufael1*, Asim Debnath2, Md Abu Bakar Siddique2, Nabil Deb Nath2

+ Author Affiliations

Clinical Epidemiology & Public Health 1 (1) 1-7 https://doi.org/10.25163/health.1110277

Submitted: 08 November 2022 Revised: 02 January 2023  Published: 05 January 2023 

Abstract

Microbial therapeutics are opening up exciting new possibilities in the fight against breast cancer. While traditional treatments like surgery, chemotherapy, and immunotherapy have saved countless lives, they often come with harsh side effects, the risk of resistance, and sometimes, the cancer coming back. That is where microbes, especially genetically engineered bacteria, are showing promise. These tiny organisms can be engineered to target and attack tumor cells, deliver medication precisely where it is needed, and even enhance the body’s immune system's ability to fight back more effectively. Increasingly, research is also revealing the importance of the human microbiome, the trillions of microbes that live in and on us, in shaping the development of cancer and the effectiveness of treatments. By adjusting the microbiome or introducing beneficial bacteria, we may be able to enhance the effectiveness of current therapies and help patients experience improved well-being throughout their treatment. Of course, we are still facing challenges. Ensuring safety, determining the most effective ways to deliver these therapies, and navigating complex regulations are all crucial steps ahead. However, the potential is real. This review examines the current state of science, recent breakthroughs, and what the future may hold for utilizing microbes as powerful allies in breast cancer care.

Keywords: Microbial Therapeutics, Breast Cancer, Engineered Bacteria, Tumor Targeting, Gut Microbiome.

References

Aarnoutse, R., Ziemons, J., Hillege, L.E., de Vos-Geelen, J., de Boer, M., Bisschop, S.M.P., Vriens, B.E.P.J., Vincent, J., van de Wouw, A.J., Le, G.N., et al. (2022). Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy. NPJ Breast Cancer, 8, 89.

Al-Nedawe, RAD and Yusof ZNB. (2023). Cyanobacteria as a Source of Bioactive Compounds with Anticancer, Antibacterial, Antifungal, and Antiviral Activities: A Review. Microbial Bioactives, Vol 6, Article 2.

Baindara, P., Gautam, A., Raghava, G.P.S., & Korpole, S. (2017). Anticancer properties of a defensin-like class IId bacteriocin, Laterosporulin 10. Scientific Reports, 7, 46541.

Bernardo, G., Le Noci, V., Ottaviano, E., De Cecco, L., Camisaschi, C., Guglielmetti, S., Di Modica, M., Gargari, G., Bianchi, F., Indino, S., et al. (2023). Reduction of Staphylococcus epidermidis in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness: Cancer Letters, 555, 216041.

Bilenduke, E., Sterrett, J.D., Ranby, K.W., Borges, V.F., Grigsby, J., Carr, A.L., Kilbourn, K., & Lowry, C.A. (2022). Impacts of breast cancer and chemotherapy on gut microbiome, cognitive functioning, and mood relative to healthy controls. Scientific Reports, 12, 19547.

Cai, Z., Sanchez, A., Shi, Z., Zhang, T., Liu, M., & Zhang, D. (2011). Activation of Toll-like Receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Research, 71, 2466–2475.

German, R., Marino, N., Hemmerich, C., Podicheti, R., Rusch, D.B., Stiemsma, L.T., Gao, H., Xuei, X., Rockey, P., & Storniolo, A.M. (2023). Exploring breast tissue microbial composition and the association with breast cancer risk factors. Breast Cancer Research, 25, 82.

Gonder LY, Aydin B, Ates YC, Parilti DN, Acik L and Cerci A. (2023). Antimicrobial, Antioxidant, Cytotoxic, DNA Protective Activities, and Molecular Docking Studies of the Methanolic Extract of Salvia siirtica Kahraman, Celep & Dogan sp. Nov. (Lamiaceae). Microbial Bioactives, Vol. 6, Article 1.

Hidaka, A., Hamaji, Y., Sasaki, T., Taniguchi, S., & Fujimori, M. (2007). Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy. Bioscience, Biotechnology, and Biochemistry, 71, 2921–2926.

Horigome, A., Okubo, R., Hamazaki, K., Kinoshita, T., Katsumata, N., Uezono, Y., Xiao, J., & Matsuoka, Y. (2019). Association between blood omega-3 polyunsaturated fatty acids and the gut microbiota among breast cancer survivors. Beneficial Microbes, 10, 751–758.

Karami, P., Goli, H.R., Abediankenari, S., Chandani, S.R., Jafari, N., Ghasemi, M., & Ahanjan, M. (2023). Anti-tumor effects of Bacteroides fragilis and Bifidobacterium bifidum culture supernatants on mouse breast cancer. Gene Reports, 33, 101815.

Kaur, S., & Kaur, S. (2015). Bacteriocins as potential anticancer agents. Frontiers in Pharmacology, 6, 272.

Khan, M. S. Sultan, Haque, S., & Fakruddin, Md. (2023). Challenges of Breast Cancer Treatment through Microbial Therapeutic Delivery—Journal of Angiotherapy, 7(1).

Khan, S.H. (2023). The significance of dysbiosis in the gut microbiome to HCV infection and disease progression. Microbial Bioactives, 6, Article 3.

Lakey, J.H., & Slatin, S.L. (2001). Pore-forming colicins and their relatives. In Van Der Goot, F.G. (Ed.), Pore-Forming Toxins (pp. 131–161). Springer: Berlin/Heidelberg, Germany.

Maroof, H., Hassan, Z.M., Mobarez, A.M., & Mohamadabadi, M.A. (2012). Lactobacillus acidophilus could modulate the immune response against breast cancer in a murine model. Journal of Clinical Immunology, 32, 1353–1359.

Naderi, N., Mosahebi, A., & Williams, N.R. (2023). Microorganisms and breast cancer: An in-depth analysis of clinical studies. Pathogens, 13, 6.

Okubo, R., Kinoshita, T., Katsumata, N., Uezono, Y., Xiao, J., & Matsuoka, Y.J. (2019). Impact of chemotherapy on the association between fear of cancer recurrence and the gut microbiota in breast cancer survivors. Brain, Behavior, and Immunity, 85, 186–191.

Sanjana Mahbub Supty, Saadat, T.M.F., & Islam, K.T. (2023). Multidrug resistance and molecular characterization of Klebsiella spp. Isolated from the cloacal samples of broiler chickens in Bangladesh. Microbial Bioactives, 6(1), 1–11, 9419.

Shamsuddin Sultan Khan, John Anthony Catanzaro. (2023). Individualized Therapeutic Design against Lyme disease, Microbial Bioactives, 6(1), 1-8, 9391

Sayed Ul Alam Shibly, Debananda S Ningthoujam (2023). A Review of Human Microbiomes on the Regulation of  Body's Hidden Ecosystem, Microbial Bioactives, 6(1), 1-10, 9374

Sheng, J.Y., & Stearns, V. (2021). Innovating and expanding weight loss strategies for breast cancer survivors. Oncotarget, 12, 521–524.

Silva, E., de Carvalho, T.C., Parshikov, I., dos Santos, R.A., Emery, F., & Furtado, N.C. (2014). Cytotoxicity of lapachol metabolites produced by probiotics. Letters in Applied Microbiology, 59, 108–114.

Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A.M., et al. (2021). Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death & Differentiation, 28, 2778–2796.

Tzeng, A., Sangwan, N., Jia, M., Liu, C.-C., Keslar, K.S., Downs-Kelly, E., Fairchild, R.L., Al-Hilli, Z., Grobmyer, S.R., & Eng, C. (2021). Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer. Genome Medicine, 13, 60.

Urbaniak, C., Cummins, J., Brackstone, M., Macklaim, J.M., Gloor, G.B., Baban, C.K., Scott, L., O’Hanlon, D.M., Burton, J.P., Francis, K.P., et al. (2014). Microbiota of human breast tissue. Applied and Environmental Microbiology, 80, 3007–3014.

Urbaniak, C., Gloor, G.B., Brackstone, M., Scott, L., Tangney, M., & Reid, G. (2016). The microbiota of breast tissue and its association with breast cancer. Applied and Environmental Microbiology, 82, 5039–5048. https://pubmed.ncbi.nlm.nih.gov/27342554/

Viker, K.B., Steele, M.B., Iankov, I.D., Concilio, S.C., Ammayappan, A., Bolon, B., Jenks, N.J., Goetz, M.P., Panagioti, E., Federspiel, M.J., et al. (2022). Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H. pylori immunostimulatory bacterial transgene. Molecular Therapy – Methods & Clinical Development, 26, 532–546.

Yang, J., Lagishetty, V., Kurnia, P., Henning, S.M., Ahdoot, A.I., & Jacobs, J.P. (2022). Microbial and chemical profiles of commercial kombucha products. Nutrients, 14, 670.

Zhu, J., Liao, M., Yao, Z., Liang, W., Li, Q., Liu, J., Yang, H., Ji, Y., Wei, W., Tan, A., et al. (2018). Breast cancer in postmenopausal women is associated with an altered gut metagenome: microbiome, 6, 136.

PDF
Abstract
Export Citation

View Dimensions


View Plumx


View Altmetric



0
Save
0
Citation
18
View
0
Share